{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:49:57Z","timestamp":1760888997166},"reference-count":5,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n With the aim of improving the available drugs for the treatment of Chagas disease, individual enantiomers of nifurtimox were characterized. The results indicate that the enantiomers are equivalent in their\n in vitro<\/jats:italic>\n activity against a panel of\n Trypanosoma cruzi<\/jats:named-content>\n strains;\n in vivo<\/jats:italic>\n efficacy in a murine model of Chagas disease;\n in vitro<\/jats:italic>\n toxicity and absorption, distribution, metabolism, and excretion characteristics; and\n in vivo<\/jats:italic>\n pharmacokinetic properties. There is unlikely to be any therapeutic benefit of an individual nifurtimox enantiomer over the racemic mixture.\n <\/jats:p>","DOI":"10.1128\/aac.05139-14","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T01:42:34Z","timestamp":1428370954000},"page":"3645-3647","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Enantiomers of Nifurtimox Do Not Exhibit Stereoselective Anti-Trypanosoma cruzi Activity, Toxicity, or Pharmacokinetic Properties"],"prefix":"10.1128","volume":"59","author":[{"given":"Carolina B.","family":"Moraes","sequence":"first","affiliation":[{"name":"Center for Neglected Diseases Drug Discovery, Institut Pasteur Korea, Bundang-gu, Seongnam-Si, Gyeonggi-do, South Korea"}]},{"given":"Karen L.","family":"White","sequence":"additional","affiliation":[{"name":"Centre for Drug Candidate Optimisation, Monash University, Parkville, Victoria, Australia"}]},{"given":"St\u00e9phanie","family":"Braillard","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland"}]},{"given":"Catherine","family":"Perez","sequence":"additional","affiliation":[{"name":"Murdoch University, Murdoch, WA, Australia"}]},{"given":"Junghyun","family":"Goo","sequence":"additional","affiliation":[{"name":"Center for Neglected Diseases Drug Discovery, Institut Pasteur Korea, Bundang-gu, Seongnam-Si, Gyeonggi-do, South Korea"}]},{"given":"Luis","family":"Gaspar","sequence":"additional","affiliation":[{"name":"Center for Neglected Diseases Drug Discovery, Institut Pasteur Korea, Bundang-gu, Seongnam-Si, Gyeonggi-do, South Korea"},{"name":"Faculdade de Farm\u00e1cia e Instituto de Biologia Molecular Celular da Universidade do Porto, Porto, Portugal"}]},{"given":"David M.","family":"Shackleford","sequence":"additional","affiliation":[{"name":"Centre for Drug Candidate Optimisation, Monash University, Parkville, Victoria, Australia"}]},{"given":"Anabela","family":"Cordeiro-da-Silva","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia e Instituto de Biologia Molecular Celular da Universidade do Porto, Porto, Portugal"}]},{"given":"R. C. Andrew","family":"Thompson","sequence":"additional","affiliation":[{"name":"Murdoch University, Murdoch, WA, Australia"}]},{"given":"Lucio","family":"Freitas-Junior","sequence":"additional","affiliation":[{"name":"Center for Neglected Diseases Drug Discovery, Institut Pasteur Korea, Bundang-gu, Seongnam-Si, Gyeonggi-do, South Korea"}]},{"given":"Susan A.","family":"Charman","sequence":"additional","affiliation":[{"name":"Centre for Drug Candidate Optimisation, Monash University, Parkville, Victoria, Australia"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762009000400002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(87)90020-4"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-6851(98)00037-1"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep04703"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm401610c"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05139-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05139-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:11:44Z","timestamp":1645485104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05139-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1128\/AAC.05139-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.05139-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2014-12-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}